FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2024243282> ?p ?o ?g. }

• W2024243282 endingPage "17" @default.
• W2024243282 startingPage "11" @default.
• W2024243282 abstract "This paper presents a summary of the evidence review group (ERG) report into capecitabine for advanced gastric cancer (aGC). Capecitabine is an oral prodrug of 5-fluorouracil (5-FU). The decision problem addressed was the use of capecitabine (X) compared to 5-FU (F), in combination regimens with platinum agents [cisplatin (C) or oxaliplatin (O)] with or without epirubicin (E), in patients with inoperable aGC. Approximately 7000 new cases of gastric cancer are diagnosed in England and Wales every year. Of these, 80% are candidates for palliative chemotherapy and around 2900 receive such treatment. The standard UK practice for patients with aGC who are considered fit enough has consisted of a triplet regimen comprising intravenous 5-FU in combination with a platinum agent (capecitabine or oxaliplatin) and epirubicin. The manufacturer’s submission (MS) focused on direct evidence from two phase III non-inferiority randomised controlled trials (RCTs), REAL-2 (Randomized ECF for Advanced and Locally advanced oesophagogastric cancer-2; n = 1002) and ML17032 ( n = 316). REAL-2 randomised patients to four regimens (ECF, ECX, EOF and EOX) to compare 5-FU with capecitabine and cisplatin with oxaliplatin, whereas ML17032 compared CX with CF. Efficacy outcomes from these trials were pooled in an individual patient data (IPD) meta-analysis. Both RCTs demonstrated statistically significant non-inferiority of capecitabine on the outcome of overall survival (OS) assessed in the per-protocol population; equivalent results were also demonstrated for progression-free survival (PFS). The IPD meta-analysis found a statistically significant benefit in OS for capecitabine compared with 5-FU [unadjusted hazard ratio (HR): 0.87; 95% confidence interval (CI) 0.77 to 0.98, p = 0.027]. There was no evidence of a poorer safety profile for capecitabine overall, nor of any difference in quality of life (QoL) between the two fluoropyrimidines. The MS included a de novo economic evaluation based on a cost-minimisation analysis (CMA), where the costs of capecitabine-based regimens were compared with their equivalent 5-FU-based regimens in aGC. A time horizon of 5.5 cycles (each lasting for 21 days) was used in the base-case analysis, representing the duration of treatment. The results of the manufacturer’s base-case analysis showed that capecitabine regimens are associated with mean net cost savings of £1620 (ECX vs ECF), £1572 (EOX vs EOF) and £4210 (CX vs CF). The manufacturer failed to comment explicitly on the uncertainty around the estimates of efficacy and on the fact that the IPD meta-analysis suggests that capecitabine may actually be more effective on average. Further analyses exploring additional costs incurred by the UK NHS from extending survival duration showed that these are unlikely to have a material effect on conclusions. A full probabilistic analysis was not performed; however, the evidence explored by the MS and ERG is consistent in suggesting that capecitabine has a lower mean cost than 5-FU-based regimens. The submission was considered to contain convincing evidence of the non-inferiority of capecitabine to 5-FU on survival; this evidence was considered to be applicable to UK practice. Although some uncertainty remains, the ERG deemed CMA to be an appropriate framework with which to analyse this decision problem. Overall cost estimates for the CMA were generated appropriately and were robust to uncertainties regarding assumptions and sources. At the time of writing, the guidance document issued by NICE on 28 July 2010 states that capecitabine in combination with a platinum-based regimen is recommended for the first-line treatment of inoperable advanced gastric cancer." @default.
• W2024243282 created "2016-06-24" @default.
• W2024243282 creator A5020147234 @default.
• W2024243282 creator A5043297254 @default.
• W2024243282 creator A5051549038 @default.
• W2024243282 creator A5053603345 @default.
• W2024243282 creator A5060049178 @default.
• W2024243282 creator A5070161423 @default.
• W2024243282 creator A5073128022 @default.
• W2024243282 creator A5090021812 @default.
• W2024243282 date "2010-10-01" @default.
• W2024243282 modified "2023-09-26" @default.
• W2024243282 title "Capecitabine for the treatment of advanced gastric cancer" @default.
• W2024243282 cites W2127773543 @default.
• W2024243282 cites W2128328462 @default.
• W2024243282 cites W2138732660 @default.
• W2024243282 cites W2145441649 @default.
• W2024243282 cites W2167571044 @default.
• W2024243282 doi "https://doi.org/10.3310/hta14suppl2/02" @default.
• W2024243282 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21047486" @default.
• W2024243282 hasPublicationYear "2010" @default.
• W2024243282 type Work @default.
• W2024243282 sameAs 2024243282 @default.
• W2024243282 citedByCount "9" @default.
• W2024243282 countsByYear W20242432822012 @default.
• W2024243282 countsByYear W20242432822014 @default.
• W2024243282 countsByYear W20242432822015 @default.
• W2024243282 countsByYear W20242432822019 @default.
• W2024243282 crossrefType "journal-article" @default.
• W2024243282 hasAuthorship W2024243282A5020147234 @default.
• W2024243282 hasAuthorship W2024243282A5043297254 @default.
• W2024243282 hasAuthorship W2024243282A5051549038 @default.
• W2024243282 hasAuthorship W2024243282A5053603345 @default.
• W2024243282 hasAuthorship W2024243282A5060049178 @default.
• W2024243282 hasAuthorship W2024243282A5070161423 @default.
• W2024243282 hasAuthorship W2024243282A5073128022 @default.
• W2024243282 hasAuthorship W2024243282A5090021812 @default.
• W2024243282 hasBestOaLocation W20242432821 @default.
• W2024243282 hasConcept C121608353 @default.
• W2024243282 hasConcept C126322002 @default.
• W2024243282 hasConcept C143998085 @default.
• W2024243282 hasConcept C168563851 @default.
• W2024243282 hasConcept C2776694085 @default.
• W2024243282 hasConcept C2777909004 @default.
• W2024243282 hasConcept C2778239845 @default.
• W2024243282 hasConcept C2780456651 @default.
• W2024243282 hasConcept C2780835546 @default.
• W2024243282 hasConcept C2780962732 @default.
• W2024243282 hasConcept C2781413609 @default.
• W2024243282 hasConcept C2908647359 @default.
• W2024243282 hasConcept C526805850 @default.
• W2024243282 hasConcept C530470458 @default.
• W2024243282 hasConcept C71924100 @default.
• W2024243282 hasConcept C99454951 @default.
• W2024243282 hasConceptScore W2024243282C121608353 @default.
• W2024243282 hasConceptScore W2024243282C126322002 @default.
• W2024243282 hasConceptScore W2024243282C143998085 @default.
• W2024243282 hasConceptScore W2024243282C168563851 @default.
• W2024243282 hasConceptScore W2024243282C2776694085 @default.
• W2024243282 hasConceptScore W2024243282C2777909004 @default.
• W2024243282 hasConceptScore W2024243282C2778239845 @default.
• W2024243282 hasConceptScore W2024243282C2780456651 @default.
• W2024243282 hasConceptScore W2024243282C2780835546 @default.
• W2024243282 hasConceptScore W2024243282C2780962732 @default.
• W2024243282 hasConceptScore W2024243282C2781413609 @default.
• W2024243282 hasConceptScore W2024243282C2908647359 @default.
• W2024243282 hasConceptScore W2024243282C526805850 @default.
• W2024243282 hasConceptScore W2024243282C530470458 @default.
• W2024243282 hasConceptScore W2024243282C71924100 @default.
• W2024243282 hasConceptScore W2024243282C99454951 @default.
• W2024243282 hasFunder F4320334661 @default.
• W2024243282 hasIssue "Suppl 2" @default.
• W2024243282 hasLocation W20242432821 @default.
• W2024243282 hasLocation W20242432822 @default.
• W2024243282 hasOpenAccess W2024243282 @default.
• W2024243282 hasPrimaryLocation W20242432821 @default.
• W2024243282 hasRelatedWork W2002532865 @default.
• W2024243282 hasRelatedWork W2019962863 @default.
• W2024243282 hasRelatedWork W2077919698 @default.
• W2024243282 hasRelatedWork W2297997985 @default.
• W2024243282 hasRelatedWork W2376908333 @default.
• W2024243282 hasRelatedWork W2381117398 @default.
• W2024243282 hasRelatedWork W2944281980 @default.
• W2024243282 hasRelatedWork W3013662455 @default.
• W2024243282 hasRelatedWork W3093809504 @default.
• W2024243282 hasRelatedWork W4254565408 @default.
• W2024243282 hasVolume "14" @default.
• W2024243282 isParatext "false" @default.
• W2024243282 isRetracted "false" @default.
• W2024243282 magId "2024243282" @default.
• W2024243282 workType "article" @default.